表紙
市場調査レポート

急性感音難聴 - パイプライン製品の分析

Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 321895
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
急性感音難聴 - パイプライン製品の分析 Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 48 Pages
概要

急性感音難聴では、突然の聴力低下、もしくは数日の間に徐々に聴力が減少します。会話が聞こえにくい、高音域が聞こえにくい、音が過剰に大きくまたは小さく聞こえるといった症状を呈します。

当レポートでは、急性感音難聴に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

急性感音難聴の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Nordmark Arzneimittel GmbH & Co. KG 14
  • Orbis Biosciences, Inc. 15
  • Otologic Pharmaceutics, Inc. 16
  • Pfizer Inc. 17
  • Sound Pharmaceuticals, Inc. 18
  • Xigen SA 19

治療薬の評価

  • 単独療法の製品
  • ■併用療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (acetylcysteine + disufenton sodium)
  • ancrod
  • betamethasone valerate
  • PF-04958242
  • Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss
  • SPI-1005
  • Stem Cell Therapy for Sensorineural Hearing Loss
  • XG-102

パイプライン製品の最新動向

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8249IDB

Summary

Global Markets Direct's, 'Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016', provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Sensorineural Hearing Loss and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Sensorineural Hearing Loss
  • The report reviews pipeline therapeutics for Acute Sensorineural Hearing Loss by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Sensorineural Hearing Loss therapeutics and enlists all their major and minor projects
  • The report assesses Acute Sensorineural Hearing Loss therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Sensorineural Hearing Loss

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Sensorineural Hearing Loss
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Sensorineural Hearing Loss pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Acute Sensorineural Hearing Loss Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Acute Sensorineural Hearing Loss - Overview 7
  • Acute Sensorineural Hearing Loss - Therapeutics under Development by Companies 8
  • Acute Sensorineural Hearing Loss - Pipeline Products Glance 9
  • Late Stage Products 9
  • Clinical Stage Products 10
  • Early Stage Products 11
  • Acute Sensorineural Hearing Loss - Products under Development by Companies 12
  • Acute Sensorineural Hearing Loss - Companies Involved in Therapeutics Development 13
  • Nordmark Arzneimittel GmbH & Co. KG 13
  • Orbis Biosciences Inc 14
  • Otologic Pharmaceutics, Inc. 15
  • Pragma Therapeutics 16
  • Xigen SA 17
  • Acute Sensorineural Hearing Loss - Therapeutics Assessment 18
  • Assessment by Monotherapy Products 18
  • Assessment by Combination Products 19
  • Assessment by Target 20
  • Assessment by Mechanism of Action 22
  • Assessment by Route of Administration 24
  • Assessment by Molecule Type 26
  • Drug Profiles 28
  • (acetylcysteine + disufenton sodium) - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • ancrod - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • betamethasone valerate ER - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • OR-102 - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • Otopotin - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • Otostem - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • Small Molecules for Sensorineural Hearing Loss - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • Small Molecules to Agonize mGlu7 for Acute Sensorineural Hearing Loss - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss - Drug Profile 37
  • Product Description 37
  • Mechanism Of Action 37
  • R&D Progress 37
  • XG-102 - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • Acute Sensorineural Hearing Loss - Dormant Projects 42
  • Acute Sensorineural Hearing Loss - Product Development Milestones 43
  • Featured News & Press Releases 43
  • Jun 17, 2016: Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness 43
  • Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss 43
  • Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery 44
  • May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111 44
  • Nov 19, 2014: Otologic Pharmaceutics Initiates Phase 1 Clinical Study of NHPN-1010 for Hearing Disorders 45
  • Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 46
  • Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 46
  • Appendix 47
  • Methodology 47
  • Coverage 47
  • Secondary Research 47
  • Primary Research 47
  • Expert Panel Validation 47
  • Contact Us 47
  • Disclaimer 48

List of Tables

  • Number of Products under Development for Acute Sensorineural Hearing Loss, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Late Stage Development, H2 2016 9
  • Comparative Analysis by Clinical Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Development, H2 2016 11
  • Products under Development by Companies, H2 2016 12
  • Acute Sensorineural Hearing Loss - Pipeline by Nordmark Arzneimittel GmbH & Co. KG, H2 2016 13
  • Acute Sensorineural Hearing Loss - Pipeline by Orbis Biosciences Inc, H2 2016 14
  • Acute Sensorineural Hearing Loss - Pipeline by Otologic Pharmaceutics, Inc., H2 2016 15
  • Acute Sensorineural Hearing Loss - Pipeline by Pragma Therapeutics, H2 2016 16
  • Acute Sensorineural Hearing Loss - Pipeline by Xigen SA, H2 2016 17
  • Assessment by Monotherapy Products, H2 2016 18
  • Assessment by Combination Products, H2 2016 19
  • Number of Products by Stage and Target, H2 2016 21
  • Number of Products by Stage and Mechanism of Action, H2 2016 23
  • Number of Products by Stage and Route of Administration, H2 2016 25
  • Number of Products by Stage and Molecule Type, H2 2016 27
  • Acute Sensorineural Hearing Loss - Dormant Projects, H2 2016 42

List of Figures

  • Number of Products under Development for Acute Sensorineural Hearing Loss, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Clinical Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Assessment by Monotherapy Products, H2 2016 18
  • Number of Products by Targets, H2 2016 20
  • Number of Products by Stage and Targets, H2 2016 20
  • Number of Products by Mechanism of Actions, H2 2016 22
  • Number of Products by Stage and Mechanism of Actions, H2 2016 22
  • Number of Products by Routes of Administration, H2 2016 24
  • Number of Products by Stage and Routes of Administration, H2 2016 24
  • Number of Products by Molecule Types, H2 2016 26
  • Number of Products by Stage and Molecule Types, H2 2016 26
Back to Top